Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of plaque psoriasis (FDA-approved)
Mild to moderate pain,Pain accompanied by fever
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Calcipotriene undergoes hepatic metabolism primarily via cytochrome P450 (CYP) enzymes, including CYP24A1. Betamethasone dipropionate is metabolized in the liver via CYP3A4.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Calcipotriene: ~94% bound to plasma proteins; betamethasone dipropionate: ~64% bound (predominantly albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Calcipotriene: >1 L/kg (extensive tissue distribution); betamethasone dipropionate: not well characterized, likely large due to lipophilicity.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Topical: minimal systemic absorption (<1% for calcipotriene, ~10-15% for betamethasone dipropionate via inflamed skin).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment due to potential for systemic absorption.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment due to potential for systemic corticosteroid effects.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Safety and efficacy in children <12 years have not been established. For children ≥12 years, apply once daily to affected areas, limit use to <30 g/week, and avoid prolonged use.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No specific dose adjustment required, but use with caution due to increased risk of skin atrophy and systemic effects. Avoid prolonged use and apply to limited areas.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
None.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.,Local adverse reactions may include skin atrophy, striae, telangiectasias, burning, pruritus, folliculitis, and allergic contact dermatitis.,May cause hypercalcemia and hypercalciuria due to calcipotriene component; monitor serum and urine calcium levels in patients with renal impairment or high doses.,Avoid use on face, groin, axillae, or intertriginous areas due to increased risk of adverse effects.,Not recommended for long-term continuous use due to potential for skin atrophy and systemic effects.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any component of the formulation.,Patients with known calcium metabolism disorders (e.g., hypercalcemia, vitamin D toxicity).,Patients with known or suspected skin infections, including viral (e.g., herpes simplex, varicella), fungal, or bacterial infections.,Use on eroded, ulcerated, or exudative skin.
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
No significant food interactions. No dietary restrictions necessary for this topical medication.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show increased risk of cleft palate and fetal growth restriction. In humans, first-trimester use of potent corticosteroids is associated with a small increased risk of oral clefts (OR 1.5). Second/third trimester: Prolonged use may cause fetal adrenal suppression and low birth weight. Avoid application to large areas (>30% BSA) or under occlusion.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Minimal systemic absorption after topical use. No specific M/P ratio available. Exercise caution: avoid application to breast area to prevent infant ingestion. Monitor infant for signs of adrenal suppression (rare). Use lowest effective dose for shortest duration.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No dose adjustment needed for topical use. However, restrict application to <30% body surface area and avoid prolonged treatment; use shortest possible duration. Systemic absorption may increase with psoriatic skin barrier disruption; monitor for corticosteroid side effects.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Apply only to psoriatic plaques, not to normal skin or flexures. Maximum weekly dose: 100g. Avoid occlusion. Use with caution on face, genitals, and intertriginous areas due to risk of corticosteroid atrophy. Discontinue if hypersensitivity develops. Monitor for hypercalcemia if used on extensive areas. Not recommended for use in children under 18 years.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
For external use only.,Apply once daily to psoriatic lesions only, avoiding unaffected skin.,Do not use more than 100 grams per week.,Do not cover with bandages or tight dressings.,Wash hands after application unless treating hands.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use on face, armpits, or groin unless directed.,Inform your healthcare professional if you experience burning, itching, or skin thinning.,Use only on children under 18 if specifically prescribed.,Do not use for more than 4 weeks without medical evaluation.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
"Coadministration of Betamethasone, a potent corticosteroid, may reduce the therapeutic efficacy of Miglustat, a glucosylceramide synthase inhibitor used for Gaucher disease and Niemann-Pick type C. Betamethasone can induce hepatic CYP3A4 isoenzymes, potentially increasing the metabolism of Miglustat, though Miglustat is primarily renally excreted and not extensively metabolized. The interaction may also involve corticosteroid-mediated alterations in drug transport or GlcCer synthesis pathways, leading to decreased Miglustat plasma concentrations and diminished clinical response, including worsening of neurological symptoms in Niemann-Pick disease."
"Concomitant use of betamethasone, a corticosteroid, with donepezil, a cholinesterase inhibitor used in Alzheimer's disease, may increase the risk of gastrointestinal adverse effects including gastric ulceration and hemorrhage. Corticosteroids inhibit prostaglandin synthesis and mucosal protection, while donepezil enhances cholinergic tone, increasing gastric acid secretion. This additive effect on the gastric mucosa can lead to clinically significant ulcer formation or gastrointestinal bleeding, particularly in elderly patients."
"Betamethasone, a potent corticosteroid, can induce hyperglycemia and dyslipidemia, potentially counteracting the lipid-lowering effects of atorvastatin. Concurrent use may increase the risk of corticosteroid-related adverse effects such as fluid retention, hyperglycemia, and myopathy. Atorvastatin may also increase systemic exposure to corticosteroids via inhibition of CYP3A4, though this interaction is generally not clinically significant."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is: Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is classified as Category C. Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.